Prognostic significance of CD38 in M2 subtype of acute myeloid leukemia
LU Yejian1 QIU Lanlan2 WANG Lili1
1.Department of Hematology, General Hospital of PLA, Beijing 100853, China;
2.Department of Hematology, Beijing Shijitan Hospital of Capital Medical University, Beijing 100038, China
Abstract：Objective To investigate the expression level of CD38 in the M2 subtype of acute myeloid leukemia and its effect on the prognosis of patients. Methods From January 2012 to December 2015, in PLA General Hospital, 47 patients with primary M2 subtype of acute myeloid leukemia were collected. The expression level of CD38 on leukemic cells was detected by flow cytometry. The clinical data and laboratorial characteristics and the survival status were compared between these patients, and the prognostic significance of CD38 was analyzed retrospectively with the combination of the most common genetic aberration of t(8;21) translocation in this type of leukemia. Results The rate of CD38+ patients was 100% in the M2 subtype of patients with t (8;21) translocation, which was higher than the 73.9% of CD38+ patients in non-t (8;21) patients (P = 0.02). The remission rate after the induction therapy in the CD38- patients with non-t (8;21) was lower than those in the CD38+ patients with or without t (8;21) translocation (50.0%, 88.2%, 95.8%, P = 0.03). The survival analysis showed that the 3-year EFS rate of these three cohorts was 16.7%, 38.1% and 58.7%, respectively, the differences were not statistically significant (P ＞ 0.05), while the 5-year OS rate of the CD38-patients was much lower than those in the CD38+ patients with or without t (8;21) translocation (16.7%, 44.0%, 47.2%, P = 0.03). Conclusion CD38 expression has a positive correlation with t(8;21) in the M2 subtype of acute myeloid leukemia, and the downregulation of CD38 expression is one of the hallmarks of poor prognosis in this subtype, which is expected to guide the prognostic stratification and personalized therapy of the patients.
[1] Byun JM，Kim YJ，Yoon HJ，et al. Cytogenetic profiles of 2806 patients with acute myeloid leukemia-a retrospective multicenter nationwide study [J]. Ann Hematol，2016，95（8）：1223-1232.
[2] Li X，Li X，Xie W，et al. Comprehensive profile of cytogenetics in 2308 Chinese children and adults with de novo acute myeloid leukemia [J]. Blood Cells Mol Dis，2012，49（2）：107-113.
[3] Estey E. Acute myeloid leukemia：2016 Update on risk-stratification and management [J]. Am J Hematol，2016，91（8）：824-846.
[4] Krauth MT，Eder C，Alpermann T，et al. High number of additional genetic lesions in acute myeloid leukemia with t（8；21）/RUNX1-RUNX1T1： frequency and impact on clinical outcome [J]. Leukemia，2014，28（7）：1449-1458.
[5] Wu AY，Yang HC，Lin CM，et al. The transcriptome study of subtype M2 acute myeloblastic leukemia [J]. Cell Biochem Biophys，2015，72（3）：653-656.
[6] Medinger M，Lengerke C，Passweg J. Novel Prognostic and Therapeutic mutations in acute myeloid leukemia [J]. Cancer Genomics Proteomics，2016，13（5）：317-329.
[7] Deaglio S，Mehta K，Malavasi F. Human CD38：a（r）evo-lutionary story of enzymes and receptors[J]. Leuk Res，2001，25（1）：1-12.
[8] Mehta K，Shahid U，Malavasi F. Human CD38，a cell-surface protein with multiple functions [J]. Faseb J，1996，10（12）：1408-1417.
[9] 向立丽，邱国强，谢晓宝，等. CD34+/CD38low/-/CD123+细胞表达水平对急性髓系白血病预后的意义[J].中国实验血液学杂志，2017，25（1）：61-65.
[10] Khan N，Freeman SD，Virgo P，et al. An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients： blood frequency of CD34+ CD38 low blasts [J]. Br J Hae-matol，2015，170（1）：80-84.
[11] 王建祥.成人急性髓系白血病（非急性早幼粒细胞白血病）中国诊疗指南[J].中华血液学杂志，2011，32（11）：804-807.
[12] Shaffer LG， Tommerup N. ISCN （2005）： an international system for human cytogenetic nomenclature [S]. Basel：S Karger AG，2005.
[13] Dohner H，Weisdorf DJ，Bloomfield CD. Acute myeloid leukemia [J]. N Engl J Med，2015，373（12）：1136-1152.
[14] Cario G，Rhein P，Mitlohner R，et al. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol [J]. Haematologica，2014，99（1）：103-110.
[15] Guo RJ，Atenafu EG，Schimmer AD，et al. Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1，FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia [J]. 2017.doi： 10.1111/ijlh.12649 . [Epub ahead of print]
[16] Nakase K，Kita K，Kyo T，et al. Prognostic relevance of cytokine receptor expression in acute myeloid leukemia：interleukin-2 receptor alpha-chain （CD25） Expression predicts a poor prognosis [J]. PLoS One，2015，10（9）：e0128998.
[17] Basturk A，Akinci S，Hacibekiroglu T，et al. Prognostic significance of flow cytometry findings in Turkish adult acute leukemia patients [J]. Eur Rev Med Pharmacol Sci，2015，19（18）：3360-3366.
[18] Zhou J，Chng WJ. Identification and targeting leukemia stem cells： The path to the cure for acute myeloid leukemia [J]. World J Stem Cells，2014，6（4）：473-484.
[19] Won EJ，Kim HR，Park RY，et al. Direct confirmation of quiescence of CD34+CD38- leukemia stem cell populations using single cell culture， their molecular signature and clinicopathological implications [J]. BMC Cancer，2015，15：217.
[20] Costello RT，Mallet F，Gaugler B，et al. Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis，reduced immunogenicity，and impaired dendritic cell transformation capacities [J]. Cancer Res，2000，60（16）：4403-4411.
[21] Lapidot T，Sirard C，Vormoor J，et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice [J]. Nature，1994，367（6464）：645-648.
2017, Vol. 14 
京公网安备 11010502046598号